Boyce Sarah insider trades
Boyce Sarah has filed 40 Form 4s with the SEC that we hold, for RNAM (President and CEO, Director), OmniAb, Inc. (OABI) (Director), Contineum Therapeutics, Inc. (CTNM) (Director) and Atrium Therapeutics, Inc. (RNA) (Director), among 5 companies in all. Across all of them we count 2 purchases worth $101.3K and 29 sales worth $33.1M reported on Form 4. In the last 12 months: 0 purchases ($0) and 3 sales ($1.7M). The largest single trade was a sale of 164,233 shares of RNA worth $6.6M, dated 2024-06-13. The first filing on our record is dated 2022-03-15 and the latest 2026-09-22.
RNAM
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-08-15 | S, sale reported on Form 4 | 100 | $2.2K | 2022-08-17 |
| 2022-08-24 | S, sale reported on Form 4 | 35,045 | $799.0K | 2022-08-26 |
| 2022-08-25 | S, sale reported on Form 4 | 14,855 | $342.7K | 2022-08-26 |
| 2023-02-01 | S, sale reported on Form 4 | 900 | $21.8K | 2023-02-03 |
| 2023-02-02 | S, sale reported on Form 4 | 45,879 | $1.1M | 2023-02-03 |
| 2023-02-03 | S, sale reported on Form 4 | 3,221 | $78.1K | 2023-02-03 |
| 2024-01-22 | S, sale reported on Form 4 | 5,092 | $51.6K | 2024-01-23 |
| 2024-03-01 | S, sale reported on Form 4 | 84,000 | $1.7M | 2024-03-05 |
| 2024-03-08 | S, sale reported on Form 4 | 84,000 | $1.8M | 2024-03-12 |
| 2024-03-12 | S, sale reported on Form 4 | 28,000 | $633.6K | 2024-03-12 |
| 2024-04-02 | S, sale reported on Form 4 | 28,000 | $735.0K | 2024-04-03 |
| 2024-05-07 | S, sale reported on Form 4 | 28,000 | $715.1K | 2024-05-07 |
| 2024-06-04 | S, sale reported on Form 4 | 28,000 | $767.8K | 2024-06-05 |
| 2024-06-12 | S, sale reported on Form 4 | 100,000 | $3.6M | 2024-06-14 |
| 2024-06-13 | S, sale reported on Form 4 | 164,233 | $6.6M | 2024-06-14 |
| 2024-06-14 | S, sale reported on Form 4 | 35,767 | $1.4M | 2024-06-14 |
| 2024-06-18 | S, sale reported on Form 4 | 32,074 | $1.3M | 2024-06-20 |
| 2024-07-09 | S, sale reported on Form 4 | 28,000 | $1.1M | 2024-07-11 |
| 2024-08-06 | S, sale reported on Form 4 | 28,000 | $1.2M | 2024-08-07 |
| 2024-09-23 | S, sale reported on Form 4 | 32,880 | $1.4M | 2024-09-23 |
| 2024-12-18 | S, sale reported on Form 4 | 31,855 | $1.0M | 2024-12-19 |
| 2025-01-21 | S, sale reported on Form 4 | 5,659 | $161.8K | 2025-01-23 |
| 2025-01-21 | S, sale reported on Form 4 | 4,738 | $135.5K | 2025-01-23 |
| 2025-03-20 | S, sale reported on Form 4 | 31,540 | $979.6K | 2025-03-21 |
| 2025-08-28 | S, sale reported on Form 4 | 25,000 | $1.2M | 2025-08-29 |
| 2025-09-05 | S, sale reported on Form 4 | 50,000 | $2.5M | 2025-09-05 |
| 2026-01-07 | S, sale reported on Form 4 | 8,576 | $619.4K | 2026-01-09 |
| 2026-01-21 | S, sale reported on Form 4 | 6,394 | $463.2K | 2026-01-23 |
| 2026-01-21 | S, sale reported on Form 4 | 7,993 | $579.1K | 2026-01-23 |
OmniAb, Inc. (OABI)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-11-09 | P, purchase reported on Form 4 | 21,000 | $57.5K | 2022-11-14 |
| 2022-11-10 | P, purchase reported on Form 4 | 15,000 | $43.8K | 2022-11-14 |
Contineum Therapeutics, Inc. (CTNM)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Atrium Therapeutics, Inc. (RNA)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Ligand Pharmaceuticals INC (LGND)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1629383) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms